• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Feb. 1

Aurobindo Pharma Ltd has received tentative approval from the US Food & Drug Administration (USFDA) to manufacture and market Sumatriptan Succinate tablets in 25mg, 50mg and 100mg. The approval was 63rd Abbreviated New Drug Approval (ANDA) approval for the Hyderabad-based company. Sumatriptan Succinate tablets are the generic equivalent of GlaxoSmithKline’s Imitrex tablets, which are indicated for the treatment of acute migraine headache. The annual sales of Suma triptan Succinate tablets in the US were approximately $950 million in the last fiscal year, the release added.

— Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Glenmark ends drug deal with Merck

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line